Delta variant lowers COVID-19 vaccine effectiveness to 66%; Johnson & Johnson reports booster shot results; cancer center reports mask, vaccine preferences of patients.
As the Delta variant spread, COVID-19 vaccine effectiveness dropped from 90% to approximately 66%, according to a report from the CDC Tuesday. The first analysis from the ongoing HEROES-RECOVER study, which includes more than 4000 health care workers and other frontline workers in 6 states, looked at vaccine effectiveness estimates from December 14, 2020, to April 10, 2021, before the Delta variant; the latest figure updates the testing period to August 14. Researchers emphasized that a 66% effectiveness rate shows that vaccines are still protecting people from contracting the virus, STAT News reported.
Receiving a booster shot of the Johnson & Johnson (J&J) vaccine dramatically increases the levels of antibodies against COVID-19, the company reported Wednesday. Multiple studies suggest higher levels of antibodies are linked to higher rates of protection, especially against the Delta variant. However, the lack of data regarding other parts of the immune system like T cells means there is not a precise estimate on the effectiveness of the booster shot against COVID-19. The New York Times said J&J will submit the data to the FDA and, if authorized, the Biden administration may provide booster shots 8 months after initial vaccination.
Patients with cancer overwhelmingly prefer that their health care providers are vaccinated against COVID-19 and wear masks, according to a survey conducted by Florida Cancer Specialists & Research Institute (FCS). The online survey included more than 6800 patients with cancer to assess patient reaction to FCS’s recent mandate for physicians and employees to be fully vaccinated for COVID-19 by October 1, 2021, with the first dose being administered no later than August 31, 2021. The majority (88%) said it was important to them that FCS physicians, nurses and staff are fully vaccinated against COVID-19, and 67% said it was “extremely important.” Regardless if they are vaccinated, 88% also said it was important that their FCS providers wear a mask.
Dr Lucio Gordan Discusses Updated Guidelines Addressing 1q Abnormalities in Multiple Myeloma
October 27th 2023Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
Listen
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More